| Revenue growth | 33% YoY growth to ₹418 Cr; base business up 37%. |
|---|---|
| Margins | EBITDA margin expanded to 18.4% from 11% YoY. |
| Demand visibility | Strong demand in base business; Ibuprofen seeing volume recovery. |
| Management confidence | Cautiously optimistic; requesting patience during strategic business review. |
Growth
Revenue grew 33% YoY to ₹418 Cr, driven by Ibuprofen and the base business.
Outlook
Review of Ibuprofen business strategic options to conclude in twelve weeks.
Risks
West Asia crisis impacts raw material costs; Ibuprofen margins remain volatile and commodity-dependent.
Last quarter's promises, checked
Delivered
- Ibuprofen strategic review by H1 → Results expected in H1 (= BEAT)
- Net debt reduction sub-₹450Cr by March '27 → ₹114Cr H1 reduction (= BEAT)
- Base business EBITDA margin ~25% → Maintained at ~25% level (= BEAT)
Partly delivered
- Revenue growth 10% target → H1 growth significantly higher but volatile (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹653.80
- Market cap
- ₹3,149 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 85.3×Sector 46.1×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Investor Presentation: Key Takeaways
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹28.5 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences will issue a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up rights equity shares regarding outstanding call money payments.